# Xenon Plans Q1 2027 Azetukalner Study With $1.2 Billion in Cash and Securities

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52797
Published: 2026-11-10T04:12:38.000Z
Updated: 2026-11-10T04:12:38.000Z
Section: Business

> Xenon submitted a new drug application for focal seizures in Q3 2026; topline results from X-NOVA2 are expected in December.

Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner in Q1 2027 as it pursues U.S. approval for focal seizures after filing a new drug application in Q3 2026.

Xenon ended Q3 with $1.2 billion in cash, cash equivalents and marketable securities. The company expects those resources to fund operations into 2029 under current plans.

Xenon expects topline results from X-NOVA2, a study in major depressive disorder (MDD), in December 2026.